Venom Immunotherapy (VIT)

Hymenoptera® venom product supply update
January 2021
 

Please find below an update of current Hymenoptera® venom product availability from Stallergenes Greer in Australia and New Zealand:

Honey Bee venom

  • In stock in Australia 
  • In stock in New Zealand

Paper Wasp venom

  • In stock in Australia 
  • In stock in New Zealand

Yellow Jacket venom

  • In stock in Australia
  • In stock in New Zealand

We are pleased to advise that a continued supply of product by the manufacturer of Hymenoptera venom products (Jubilant HollisterStier LLC) has resulted in the ability to restore normal access to all venom products (Honey Bee, Paper Wasp and yellow Jacket) by wholesalers in both Australia and New Zealand.

For assistance with venom orders, please contact your Stallergenes Greer territory manager:

REGION

TERRITORY MANAGER

EMAIL

NSW South / ACT / QLD

Anastasia Sheludiakova

This email address is being protected from spambots. You need JavaScript enabled to view it.

NSW North

Hannah Bee

This email address is being protected from spambots. You need JavaScript enabled to view it.

VIC / TAS

Robert Vetisch

This email address is being protected from spambots. You need JavaScript enabled to view it.

VIC west

Esther Foeldes

This email address is being protected from spambots. You need JavaScript enabled to view it.

WA / SA

Aida Da Silva

This email address is being protected from spambots. You need JavaScript enabled to view it.

New Zealand

Mary McIntyre

This email address is being protected from spambots. You need JavaScript enabled to view it.

For other enquiries:

  • in Australia, please contact DHL on 1800 077 421 or by email at This email address is being protected from spambots. You need JavaScript enabled to view it.
  • in New Zealand, please contact Mary McIntyre by email at This email address is being protected from spambots. You need JavaScript enabled to view it.

For medical information enquiries, please contact Dr. Martin Rees (APAC Regional Medical Director) on This email address is being protected from spambots. You need JavaScript enabled to view it.

To report adverse events, please email This email address is being protected from spambots. You need JavaScript enabled to view it.

Registered and replacement venom products: differences in external appearance

Stallergenes Greer is continuing efforts to secure the supply of registered ALBEY® venom products. Replacement Hymenoptera® venom products and replacement sterile Greer diluents (which are both FDA registered products in the US) have been authorised by the TGA for supply in Australia under S19A(1) of the Therapeutic Goods Act and New Zealand under S26 of the Therapeutic Goods Act.

Whilst the external appearance of the replacement products and registered products differ, they are identical in terms of the:

The registered and replacement products are both delivered from the manufacturer in sterile vials within tamper-evident packaging: e.g. within sealed external plastic packaging in the case of the replacement Greer diluents, and within vials with breakable caps in the case of the registered ALBEY® diluents. In the case of the replacement Greer diluents, the Certificate of Conformance released by Greer Quality Assurance is available here:

pdfCertificate of Conformance - Albumine-Saline Diluent 9mL x25 Batch 350890.pdf255.74 KB

This document confirms that the products supplied as detailed above have passed all test requirements (e.g. sterility) and have met all defined product specifications required by the FDA.

If you remove these products from their original tamper-evident packaging to provide to third parties for administration, please explain the difference in the external appearance of the product and refer to this communication if necessary.

Stallergenes Greer understands the impact of this shortage on both patients and prescribers and are committed to ensuring reliable supply of these important products into Australia and New Zealand on an ongoing basis. We will provide further updates as soon as more information is available.

In case of future shortages, for guidance on how to make decisions about the appropriate care for patients currently receiving venom immunotherapy, and measures to avoid interruptions to therapy in high-risk patients, you may wish to refer to the following websites:

Content updated May 2021